Marker Therapeutics, Inc. Profile Avatar - Palmy Investing

Marker Therapeutics, Inc.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indic…

Biotechnology
US, Houston [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Marker Therapeutics, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of MRKR's Analysis
CIK: 1094038 CUSIP: 57055L107 ISIN: US57055L2060 LEI: - UEI: -
Secondary Listings
MRKR has no secondary listings inside our databases.